**Characterization of Oseltamivir-Resistant 2009 H1N1 Pandemic Influenza A Viruses**

Maki Kiso1, Kyoko Shinya2, Masayuki Shimojima1, Ryo Takano1, Kei Takahashi1, Hiroaki Katsura1, Satoshi Kakugawa1, Mai thi Quynh Le3, Makoto Yamashita4, Yousuke Furuta5, Makoto Ozawa6,7, Yoshihiro Kawaoka1,2,6,7,8*

1 Division of Virology, Department of Microbiology and Immunology, Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, Tokyo, Japan, 2 Division of Zoonosis, Department of Microbiology and Infectious Diseases, Graduate School of Medicine, Kobe University, Hyogo, Japan, 3 National Institute of Hygiene and Epidemiology, Hanoi, Vietnam, 4 Daiichi Sankyo Co Ltd, Shinagawa, Tokyo, Japan, 5 Toyama Chemical Co., Ltd, Toyama, Japan, 6 International Research Center for Infectious Diseases, Institute of Medical Science, University of Tokyo, Shirokanedai, Minato-ku, Tokyo, Japan, 7 Department of Pathobiological Sciences, University of Wisconsin, Madison, Wisconsin, United States of America, 8 ERATO Infection-Induced Host Responses Project, Japan Science and Technology Agency, Saitama, Japan

**Abstract**

Influenza viruses resistant to antiviral drugs emerge frequently. Not surprisingly, the widespread treatment in many countries of patients infected with 2009 pandemic influenza A (H1N1) viruses with the neuraminidase (NA) inhibitors oseltamivir and zanamivir has led to the emergence of pandemic strains resistant to these drugs. Sporadic cases of pandemic influenza have been associated with mutant viruses possessing a histidine-to-tyrosine substitution at position 274 (H274Y) in the NA, a mutation known to be responsible for oseltamivir resistance. Here, we characterized in vitro and in vivo properties of two pairs of oseltamivir-sensitive and -resistant (possessing the NA H274Y substitution) 2009 H1N1 pandemic viruses isolated in different parts of the world. An in vitro NA inhibition assay confirmed that the NA H274Y substitution confers oseltamivir resistance to 2009 H1N1 pandemic viruses. In mouse lungs, we found no significant difference in replication between oseltamivir-sensitive and -resistant viruses. In the lungs of mice treated with oseltamivir or even zanamivir, 2009 H1N1 pandemic viruses with the NA H274Y substitution replicated efficiently. Pathological analysis revealed that the pathogenicities of the oseltamivir-resistant viruses were comparable to those of their oseltamivir-sensitive counterparts in ferrets. Further, the oseltamivir-resistant viruses transmitted between ferrets as efficiently as their oseltamivir-sensitive counterparts. Collectively, these data indicate that oseltamivir-resistant 2009 H1N1 pandemic viruses with the NA H274Y substitution were comparable to their oseltamivir-sensitive counterparts in their pathogenicity and transmissibility in animal models. Our findings highlight the possibility that NA H274Y possessing oseltamivir-resistant 2009 H1N1 pandemic viruses could supersede oseltamivir-sensitive viruses, as occurred with seasonal H1N1 viruses.

**Citation:** Kiso M, Shinya K, Shimojima M, Takano R, Takahashi K, et al. (2010) Characterization of Oseltamivir-Resistant 2009 H1N1 Pandemic Influenza A Viruses. PLoS Pathog 6(8): e1001079. doi:10.1371/journal.ppat.1001079

**Editor:** Michael Farzan, Harvard Medical School, United States of America

**Received** February 1, 2010; **Accepted** July 27, 2010; **Published** August 26, 2010

**Copyright:** © 2010 Kiso et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Funding:** This work was supported by ERATO (Japan Science and Technology Agency), by a grant-in-aid for Specially Promoted Research from the Ministries of Education, Culture, Sports, Science, and Technology, by grants-in-aid from Health, Labor, and Welfare of Japan, by a Contract Research Fund for the Program of Founding Research Centers for Emerging and Reemerging Infectious Diseases, by National Institute of Allergy and Infectious Disease Public Health Service research grants, and by an NIAID-funded Center for Research on Influenza Pathogenesis (CRIP, HHSN266200700010C). The funding bodies had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**Competing Interests:** Dr. Kawaoka has received speaker’s honoraria from Chugai Pharmaceuticals, Novartis, Daiichi-Sankyo, Toyama Chemical, Wyeth, and GlaxoSmithKline; grant support from Chugai Pharmaceuticals, Daiichi Sankyo, and Toyama Chemical; is a consultant for Theraclicone and Crucell; and is a founder of FluGen.

* E-mail: kawaoka@ims.u-tokyo.ac.jp

**Introduction**

Since its emergence in early spring of 2009, 2009 pandemic influenza A (H1N1) viruses have been circulating worldwide [1]. Although most infected individuals have exhibited an uncomplicated, mild respiratory disorder, the pathogenicity of this virus is clearly higher than that of seasonal influenza viruses in animal models [2–4] and humans, including those who do not have underlying illness [5].

Although two classes of anti-influenza drugs – M2 ion channel blockers (amino-adamantines; amantadine and rimantadine) and neuraminidase (NA) inhibitors (oseltamivir and zanamivir) – are licensed, the 2009 H1N1 pandemic viruses, including the earliest isolate, are already amino-adamantine-resistant [1]. By contrast, most of the currently circulating pandemic viruses are susceptible to NA inhibitors [2,6], and therefore, pandemic influenza patients are treated with NA inhibitors in many countries. This widespread administration, however, raises concerns over the emergence and global spread of NA inhibitor-resistant 2009 H1N1 pandemic viruses.

Studies with seasonal H1N1, H3N2, and highly pathogenic avian H5N1 viruses revealed that single amino acid substitutions at several positions in or around the NA active site confer resistance to viruses against NA inhibitors [7–11]. Among these NA substitutions, a histidine-to-tyrosine substitution at position 274 (N2 numbering, H274Y) is one of the best characterized oseltamivir-resistant markers. Recently, the NA H274Y substitution has been detected in sporadic cases of oseltamivir-treated and
Author Summary

Although most of the currently circulating 2009 pandemic influenza A (H1N1) viruses are susceptible to neuraminidase (NA) inhibitors (oseltamivir and zanamivir), oseltamivir-resistant mutants have sporadically appeared. Yet, the pathogenicity and transmissibility of these oseltamivir-resistant 2009 H1N1 pandemic viruses remain unknown. Here, we compared the pathogenicity and transmissibility of two pairs of oseltamivir-sensitive and -resistant viruses in mouse and ferret models. We found that the oseltamivir-resistant viruses efficiently replicated in the lungs of mice treated with oseltamivir or even zanamivir. Further, we demonstrated that these oseltamivir-resistant viruses caused lung lesions in ferrets and efficiently transmitted between ferrets, as did their oseltamivir-sensitive counterparts. Overall, our results suggest the possibility that oseltamivir-resistant viruses could spread among humans without loss of pathogenicity.

-untreated patients infected with 2009 H1N1 pandemic viruses [12–14]; however, the pathogenicity and transmissibility of viruses possessing this NA substitution remain unknown.

To better assess the risk of the 2009 H1N1 pandemic viruses that possess the NA H274Y substitution, we studied the in vitro and in vivo properties of two NA H274Y-possessing isolates that emerged independently: A/Osaka/180/2009 (H1N1; O180r) and A/Vietnam/HCM9727/2009 (H1N1; VN32060r).

Results/Discussion

In vitro sensitivity of viruses to NA inhibitors

To test the in vitro sensitivity to various NA inhibitors of 2009 H1N1 pandemic viruses possessing the NA H274Y substitution, we measured the NA activity of O180r and VN32060r exposed to oseltamivir carboxylate (the active metabolite of oseltamivir), zanamivir, or R-125489 (the active metabolite of the experimental NA inhibition assay).

| NA inhibitors | IC_{50} Values |
|---------------|----------------|
|              | O164s | O180r | VN9727s | VN32060r |
| Oseltamivir carboxylate | 1.6 ± 0.1 | 856 | 1.63 | 811 |
| Zanamivir | 0.43 | 0.75 | 0.3 | 0.56 |
| R-125489 | 0.44 | 0.89 | 0.26 | 0.5 |

To further assess the in vitro sensitivity of oseltamivir-resistant 2009 H1N1 pandemic viruses to the NA inhibitors, we investigated the growth kinetics of the two pairs of oseltamivir-sensitive and -resistant viruses in cultured cells in the presence of oseltamivir carboxylate, zanamivir, or R-125489 (Supplementary Fig. S1). While the growth of O164s and VN9727s was severely impaired by oseltamivir carboxylate, O180r and VN32060r replicated efficiently even in the presence of oseltamivir carboxylate. By contrast, both oseltamivir and R-125489 inhibited the replication of all of the viruses tested. These results indicate that the NA H274Y substitution reduces the sensitivity of 2009 H1N1 pandemic viruses to oseltamivir, as has been shown with seasonal H1N1, H3N2, and highly pathogenic avian H5N1 viruses [7–11, 15], since the other amino acid variations among the viruses tested (Supplementary Table S1) did not account for their reduced oseltamivir sensitivity: the lower growth of O180r compared to that of O164s in the absence of antivirals (Supplementary Fig. S1) might be due to these additional amino acid differences.

Replication and antiviral sensitivity of viruses in mice

To evaluate the effect of the NA H274Y substitution on the replication of the 2009 pandemic viruses in vivo, we infected BALB/c mice with either 10^2 or 10^3 plaque-forming units (PFU) of O164s, VN9727s, O180r, or VN32060r and determined virus titers in the lungs of mice on days 3 and 6 post-infection (pi) (Fig. 1, see “Control” samples). We found that oseltamivir-resistant viruses replicated significantly better than oseltamivir-sensitive viruses at both day 3 and day 6 pi with one exception: on day 6 pi, the virus titer in the lungs of mice infected with 10^3 PFU of VN9727s was significantly higher than that of VN32060r-infected mice. These results indicate that the NA H274Y substitution does not negatively affect virus replication in the mouse lung in most settings.

Next, we tested virus sensitivity to anti-influenza drugs in mice (Fig. 1). One hour pi, mice received oseltamivir, zanamivir, CS-8958, or an experimental viral RNA polymerase inhibitor favipiravir (also known as T-705). When mice were treated with oseltamivir (80 mg/kg/day dose), the replication of the NA H274Y-possessing viruses O180r and VN32060r was not inhibited, whereas the virus titers of their oseltamivir-sensitive counterparts O164s and VN9727s were significantly reduced. These results support the results of the in vitro NA inhibition assays and growth kinetics in MDCK cells indicates that the NA H274Y substitution confers oseltamivir resistance to viruses in mice. Although the efficacy of zanamivir against an oseltamivir-resistant virus (O180r) was not prominent when mice were infected with 10^3 PFU of viruses (Fig. 1), at a lower infectious dose (10^2 PFU) of viruses, its efficacy was apparent. CS-8958 and favipiravir significantly reduced the replication of all viruses tested, indicating that these 2009 H1N1 pandemic isolates, including oseltamivir-resistant strains, are as susceptible to these experimental antiviral drugs as one of the initial isolates A/California/04/2009 (H1N1) [2].

Pathogenicity and transmissibility of viruses in ferrets

To assess the transmissibility of oseltamivir-resistant 2009 H1N1 pandemic viruses, on day 1 pi we co-housed naïve ferrets in perforated cages next to ferrets inoculated with 10^6 PFU of O164s, VN9727s, O180r, or VN32060r and collected nasal swabs from inoculated and contact ferrets on days 1, 3, 5, 7, 9, and 11 after infection and co-housing, respectively, for virological analysis (Table 2). For all viruses tested, all contact ferrets were infected with viruses via respiratory droplets from infected ferrets, although the detection of O180r in contact ferrets was delayed by up to two
Figure 1. Antiviral sensitivity of viruses in mice. Mice were intranasally inoculated with $10^2$ (A, D, G, and J) or $10^3$ PFU of O164s, O180r (A–F), VN9727s, or VN32060r (G–L). At one hour post-infection (pi), mice were administered oseltamivir, zanamivir, CS-8958, favipiravir, or distilled water and PBS (control). Ten (A, B, D, E, G, H, J, and K) or three (C, F, I, and L) mice per group were euthanized on days 3 and 6 pi and virus titers in the lungs...
Oseltamivir-Resistant Pandemic Viruses

were determined by plaque assays in MDCK cells (detection limit: 1.0 log_{10} PFU/g). Error bars indicate the standard deviations of viral titers detected in the lungs of ten or three mice. Statistical significance was assessed by use of the Student’s t-test: *, p<0.05; **, p<0.01.

doi:10.1371/journal.ppat.1001079.g001

days in all three pairs. Sequencing of the NA gene of the oseltamivir-resistant viruses (i.e., O180r and VN32060r) revealed that all of the viruses isolated from the contact ferrets retained the oseltamivir resistance-conferring tyrosine at position 274 in NA. Collectively, there were no substantial differences in transmissibility between oseltamivir-sensitive and -resistant viruses in ferrets.

To evaluate the pathogenicity of NA H274Y possessing oseltamivir-resistant 2009 H1N1 pandemic viruses, we infected ferrets with 10^6 PFU of O164s, VN9727s, O180r, or VN32060r and monitored them daily for changes in body temperature and weight, and for clinical signs. On day 6 pi, nasal turbinates, trachea, and lungs were removed for pathological analysis. All viruses tested caused respiratory symptoms such as sneezing, although no marked changes in body temperature or weight were observed (data not shown). We found no remarkable pathological differences in the extent and manifestation of disease between ferrets infected with oseltamivir-sensitive or -resistant viruses (Fig. 2). All ferrets examined had severe inflammatory changes in their respiratory tracts: rhinitis, tracheitis and bronchopneumonia with bronchadenitis (Fig. 2A and B). In addition, we found limited bronchadenitis lesions with viral antigens in four ferrets, two of which were infected with oseltamivir-sensitive viruses (either O164s or VN9727s) while the other two were infected with oseltamivir-resistant VN32060r (Fig. 2C and D). These results indicate the comparable pathogenicity of the oseltamivir-resistant viruses to their oseltamivir-sensitive counterparts in ferrets. These results also suggest that the oseltamivir-resistant 2009 H1N1 pandemic viruses have the potential to be readily transmitted among humans without loss of pathogenicity.

Here, we investigated antiviral sensitivity, pathogenicity, and transmissibility of 2009 H1N1 pandemic influenza viruses possessing the substitution NA H274Y, which is known to reduce the sensitivity of influenza viruses to oseltamivir in cultured cells, mice, and ferrets. Viruses with this NA substitution exhibited reduced sensitivity to oseltamivir with comparable replication, pathogenicity, and transmissibility compared to their oseltamivir-sensitive counterparts; these findings need to be validated in humans. The widespread administration of oseltamivir, and to a lesser extent zanamivir, will clearly contribute to the emergence of NA inhibitor-resistant viruses that retain optimal replication fitness and transmissibility in humans. Given our finding that the oseltamivir-resistant 2009 H1N1 pandemic viruses are as pathogenic and transmissible as their drug-sensitive counterparts, specific criteria for the use of NA inhibitors may need to be reconsidered.

Oseltamivir has been used extensively in patients with 2009 pandemic influenza, especially those who are immunocompromised. Approximately one-third of the oseltamivir-resistant pandemic strains have been isolated from immunocompromised patients [http://www.who.int/csr/disease/swineflu/frequently_asked_questions/antivirals/resistance/en/index.html], a possibility we predicted early in this pandemic [16]. Oseltamivir-resistant viruses readily emerge in immunocompromised patients partly because viruses can replicate to higher titers and for longer periods in immunocompromised hosts compared to those who are immunocompetent hosts [17]. Since the oseltamivir-resistant 2009 pandemic viruses are as pathogenic and transmissible as their drug-sensitive parents, immunocompromised influenza patients require special care - increased drug doses, combination therapy, and possibly isolation. In particular, combination therapy has the potential to reduce the emergence of drug-resistant mutants [18] and provide synergistic effects on the inhibition of virus replication [19–21] with no increase in adverse events [22]. Adopting such measures would help prevent the situation experienced with the oseltamivir-resistant seasonal H1N1 virus, which emerged during the 2007-2008 influenza season in Europe [23], spread, and superseded previously circulating oseltamivir-sensitive viruses [24,25].

Finally, our in vitro and in vivo experiments suggest that the experimental drugs CS-8958 and favipiravir may be promising candidates to combat 2009 H1N1 pandemic viruses.

Table 2. Virus titers in the nasal swabs of inoculated and contact ferrets.

| Virus titer (log10 PFU/ml) in animals infected with: | O164s | O180r | VN9727s | VN32060r |
|-----------|-------|-------|---------|---------|
|          | Pair 1 | Pair 2 | Pair 3 | Pair 4 | Pair 5 | Pair 6 | Pair 7 | Pair 8 | Pair 9 | Pair 10 | Pair 11 | Pair 12 |
| O164s    |       |       |        |        |        |        |        |        |        |         |         |        |
|          | i     | c     | i      | c      | i      | c      | i      | c      | i      | c        | i        | c       |
| Day 1    | 7.1   |       | 6.1    | -      | 5.9    | -      | 4.7    | -      | 4.3    | -        | 5.8      | -        |
| Day 3    | 5.1   | 1     | 4.5    | 3.7    | 4.2    | 2.0    | 3.8    | -      | 3.0    | 2.0      | -        | 5.2      |
| Day 5    | 3.7   | 5.7   | 2.1    | 4.7    | 2.8    | 6.1    | 3.1    | 6.4    | 3.2    | 5.4      | 2.7      | 3.0      |
| Day 7    | -     | -     | -      | 5.5    | -      | 4.1    | -      | 5.1    | -      | 4.7      | -        | 5.3      |
| Day 9    | -     | -     | -      | -      | -      | 1.8    | -      | 3.0    | -      | 4.7      | -        | -        |
| Day 11   | -     | -     | -      | -      | -      | -      | -      | -      | -      | -        | -        | -        |

*For pairs of ferrets, one animal was intranasally inoculated with 10^6 PFU of virus (500 μl) (inoculated ferret, i) and one day later, a naive ferret was placed in an adjacent cage (contact ferret, c). Nasal swabs were collected from all animals every other day for virus titration.

1Day 1 of co-housing of contact animals corresponds to Day 2 of infection.
2Virus titers in the nasal swabs were determined by plaque assays in MDCK cells.
3Virus not detected (detection limit: 1.0 log_{10} PFU/g).

doi:10.1371/journal.ppat.1001079.t002
Materials and Methods

Viruses and cells

We used two pairs of H1N1 pandemic virus clinical isolates; A/Osaka/164/2009 (O164s), A/Osaka/180/2009 (O180r), A/Vietnam/HCM9727/2009 (VN9727s), and A/Vietnam/HN32060/2009 (VN32060r). All of the viruses were isolated in Madin-Darby canine kidney (MDCK) cells, which were maintained in Eagle’s minimal essential medium (MEM) supplemented with 5% newborn calf serum (Sigma, St. Louis, MO) and cultured at 35°C in 5% CO₂. Tyrosine at position 275 in the NA of O180r and VN32060r was confirmed by molecular cloning and sequencing of 18 individual clones each, while the rest of the viral genome sequences were determined by direct sequencing of amplified DNA.

Antiviral compounds

Oseltamivir (oseltamivir phosphate) and oseltamivir carboxylate (the active metabolite of oseltamivir; GS4104) were prepared from Tamiflu (Roche Laboratories Inc., Basel, Switzerland). Zanamivir, CS-8958 (an experimental NA inhibitor), and R-125489 (the active metabolite of CS-8958) were synthesized at Daiichi Sankyo Co. Ltd. according to published procedures [26]. Favipiravir (an experimental broad-spectrum viral RNA polymerase inhibitor, also known as T-705), was synthesized at Toyama Chemical Co., Ltd.

NA inhibition assay

NA activity of viruses in the presence of NA inhibitor was measured by an NA inhibition assay as described previously [8,27,28]. Briefly, diluted viruses were mixed with various concentrations of NA inhibitor in 2-[N-morpholino]ethanesulfonic acid containing CaCl₂ and incubated for 30 min at 37°C. A fluorescent substrate methylumbelliferyl-N-acetylneuraminic acid (Sigma) was added to this mixture, which was then incubated for one hour at 37°C. After adding NaOH in 80% ethanol to the mixture to stop the reaction, the fluorescence of the solution was measured at an excitation wavelength of 360 nm and an emission wavelength of 465 nm and the 50% inhibitory concentration (IC₅₀) was calculated.

In vitro growth kinetics

MDCK cells were infected with viruses at a multiplicity of infection of 0.0001. One hour later, oseltamivir carboxylate,
zanamivir, R-125489 (10 μM each), or nothing (control) was added to the cells. At 0, 16, 24, 32, 40, and 48 h post-infection (pi), the supernatants of the infected cells were harvested and subjected to plaque assays in MDCK cells to determine virus titers.

Experimental infection of mice

Six-week-old female BALB/c mice (Japan SLC Inc., Shizuoka, Japan) were anesthetized with isoflurane and intranasally infected with 10^6 or 10^5 plaque-forming units (PFU) (50 μl) of viruses. One hour pi, six mice per group were administered the following antiviral compounds: (1) oseltamivir phosphate: 80 mg per kg per 400 μl (divided into two oral administrations per day) for 5 days; (2) zanamivir: 0, 8, or 25 mg per kg per 50 μl in one daily intranasal administration for 5 days; (3) CS-8958: 0.75 mg per kg per 50 μl in one intranasal administration; (4) Favipiravir: 60 or 300 mg per kg per 400 μl (divided into two oral administrations per day) for 5 days; (5) or distilled water orally (200 μl) and PBS intranasally (50 μl). Three mice per group were euthanized on days 3 and 6 pi and virus titers in the lungs were determined by plaque assays in MDCK cells.

Experimental infection of ferrets

Three-to-four-month-old male ferrets (Marshall Farms, Wollcott, NY) and six-to-eight-month-old female ferrets (Triple F Farms, Sayre, PA) were used; animals from Triple F Farms were used for the transmission study of O164s and O180r, while those from Marshall Farms were used for the rest of studies. All of the animals, which were serologically negative for currently circulating human influenza viruses (including pandemic H1N1 viruses) by haemagglutination inhibition (HI) assay, were anesthetized with ketamine and xylazine (5 mg and 0.5 mg per kg of body weight, respectively) and intranasally infected with 10^6 PFU (500 μl) of viruses. On day 6 pi, three ferrets per group were euthanized and their nasal turbinates, trachea, and lungs subjected to virological and pathological analyses. For the transmission study, on day 1 pi, three naïve ferrets per group were co-housed in a perforated cage adjacent to an inoculated ferret; ferrets were separated by a perforated divider and did not have direct contact. All ferrets were monitored daily for changes in body temperature and weight, and clinical signs. Nasal swabs of inoculated and contact ferrets were collected on days 1, 3, 5, 7, 9, and 11 after infection and co-housing, respectively, and virus titers were determined by plaque assays in MDCK cells.

Pathological examination

Nasal turbinates, trachea, and lungs of euthanized ferrets were preserved in 10% phosphate-buffered formalin. Tissues were then processed for paraffin embedding and cut into 5 μm-thick sections. One section from each tissue sample was subjected to standard hematoxylin-and-eosin (H&E) staining, while another was processed for immunohistological staining with an anti-influenza virus rabbit antibody [R.909; prepared in our laboratory] that reacts comparably with all viruses tested. Specific antigen-antibody reactions were visualized by 3,3-diaminobenzidine tetrahydrochloride staining using a Dako EnVision system (Dako Co., Ltd., Tokyo, Japan).

Ethics

Our research protocol for the use of mice and ferrets followed the University of Tokyo’s Regulations for Animal Care and Use, which was approved by the Animal Experiment Committee of the Institute of Medical Science, the University of Tokyo (approval number: 19-28). The committee acknowledged and accepted both the legal and ethical responsibility for the animals, as specified in the Fundamental Guidelines for Proper Conduct of Animal Experiment and Related Activities in Academic Research Institutions under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology, 2006.

Supporting Information

Figure S1 Growth kinetics of viruses in MDCK cells. Cells were infected with O164s (A), O180r (B), VN9727s (C), or VN32060r (D) at a multiplicity of infection of 0.0001. One hour later, oseltamivir carboxylate, zanamivir, R-125489 (10 μM each), or nothing (control) was added to the cells. The virus titers in the supernatants at the indicated times post-infection were assessed by plaque assays in MDCK cells. Error bars indicate the standard deviations of the viral titers from triplicate experiments. Found at: doi:10.1371/journal.ppat.1001079.s001 (0.27 MB TIF)

Table S1 Amino acid differences among the viruses tested. Found at: doi:10.1371/journal.ppat.1001079.s002 (0.16 MB DOC)

Acknowledgments

We thank Susan Watson and Krista Wells for editing this manuscript and Ryoko Yamao for technical assistance.

Author Contributions

Conceived and designed the experiments: MK YK. Performed the experiments: MK KS MS RT KT HK SK. Analyzed the data: KS MO YK. Contributed reagents/materials/analysis tools: MtQL MY YF. Wrote the paper: MK KS MO YK.

References

1. Dawood FS, Jain S, Finelli L, Shaw MW, Lindstrom S, et al. (2009) Emergence of a novel swine-origin influenza A (H1N1) virus in humans. N Engl J Med 360: 2605–2615.
2. Itoh Y, Shinya K, Kiso M, Watanabe T, Sakoda Y, et al. (2009) In vitro and in vivo characterization of new swine-origin H1N1 influenza viruses. Nature 460: 1021–1025.
3. Munster VJ, de Wit E, van den Brand JM, Herfst S, Schrauwen EJ, et al. (2009) Pandemic potential of the swine-origin 2009 influenza A (H1N1) virus. Nat Med 15: 695–705.
4. Gubareva LV, Kain K, Scholtissek C, Davis C, Shieh WJ, et al. (2000) Influenza virus neuraminidase inhibitors. Lancet 355: 827–835.
5. Kiso M, Mitamura K, Sakai-Tagawa Y, Shiraishi K, Kawamata C, et al. (2004) Avian flu: resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet 364: 759–765.
6. Zambon M, Hayden FG (2001) Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res 49: 147–156.
7. Zambon M, Hayden FG (2001) Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res 49: 147–156.
8. Ward P, Small I, Smith J, Suter P, Dutkowski R (2005) Oseltamivir (Tamiflu) and its potential for use in the event of an influenza pandemic. J Antimicrob Chemother 55 Suppl 1: i5–i21.
9. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, et al. (2005) Avian flu: resistance to drug-resistant H5N1 virus. Nature 437: 1108.
10. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, et al. (2005) Avian flu: resistance to drug-resistant H5N1 virus. Nature 437: 1108.
11. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, et al. (2005) Avian flu: resistance to drug-resistant H5N1 virus. Nature 437: 1108.
12. Le QM, Kiso M, Someya K, Sakai YT, Nguyen TH, et al. (2005) Avian flu: resistance to drug-resistant H5N1 virus. Nature 437: 1108.
14. Le QM, Wertheim HF, Tran ND, van Doorn HR, Nguyen TH, et al. (2010) A community cluster of oseltamivir-resistant cases of 2009 H1N1 influenza. N Engl J Med 362: 86–87.
15. Yamashita M, Tomooka T, Kakuta M, Tokumitsu A, Nasu H, et al. (2009) CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity. Antimicrob Agents Chemother 53: 186–192.
16. Neumann G, Noda T, Kawaoka Y (2009) Emergence and pandemic potential of swine-origin H1N1 influenza virus. Nature 459: 931–939.
17. Ison MG, Mushiin VP, Braciale TJ, Hayden FG, Gubareva LV (2006) Comparative activities of oseltamivir and A-322278 in immunocompetent and immunocompromised murine models of influenza virus infection. J Infect Dis 193: 765–772.
18. Ilyushina NA, Bovin NV, Webster RG, Govorkova EA (2006) Combination chemotherapy, a potential strategy for reducing the emergence of drug-resistant influenza A variants. Antiviral Res 70: 121–131.
19. Nguyen JT, Hoopes JD, Le MH, Smee DF, Patrick AK, et al. Triple combination of amantadine, ribavirin, and oseltamivir is highly active and synergistic against drug resistant influenza virus strains in vitro. PLoS One 5: e9332.
20. Ilyushina NA, Hay A, Yilmaz N, Boon AC, Webster RG, et al. (2008) Oseltamivir-ribavirin combination therapy for highly pathogenic H5N1 influenza virus infection in mice. Antimicrob Agents Chemother 52: 3898–3900.
21. Govorkova EA, Fang HB, Tan M, Webster RG (2004) Neuraminidase inhibitor-rimantadine combinations exert additive and synergistic anti-influenza virus effects in MDCK cells. Antimicrob Agents Chemother 48: 4855–4863.
22. Morrison D, Roy S, Rayner C, Amer A, Howard D, et al. (2007) A randomized, crossover study to evaluate the pharmacokinetics of amantadine and oseltamivir administered alone and in combination. PLoS ONE 2: e1305.
23. Hauge SH, Dadman S, Borgen K, Lackenby A, Hungnes O (2009) Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007–08. Emerg Infect Dis 15: 155–162.
24. Nicoll A, Giancio B, Kramarz P (2008) Observed oseltamivir resistance in seasonal influenza viruses in Europe interpretation and potential implications. Euro Surveill 13.
25. Lackenby A, Thompson CI, Democristis J (2008) The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis 21: 626–638.
26. Honda T, Kubo S, Masuda T, Arai M, Kobayashi Y, et al. (2009) Synthesis and in vivo influenza virus-inhibitory effect of ester prodrug of 4-guanidino-7-O-methyl-Neu5Ac2en. Bioorg Med Chem Lett 19: 2938–2940.
27. Gubareva LV, Webster RG, Hayden FG (2001) Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother 45: 3463–3468.
28. Hatakeyama S, Sugaya N, Ito M, Yamazaki M, Ichikawa M, et al. (2007) Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA 297: 1435–1442.